1. Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck
- Author
-
Siodlak, M.Z., Stell, P.M., Wilson, J.A., Green, J.A., Allison, R.S., Adler, D., and Squadrelli-Saraceno, M.
- Subjects
Cisplatin -- Evaluation ,Squamous cell carcinoma ,Cyclophosphamide -- Evaluation ,Vincristine -- Evaluation ,Chemotherapy -- Evaluation ,Head and neck cancer ,Health - Abstract
Squamous cell carcinoma, a cancer of the cells that form the skin and other membranes, is very hard to treat when it occurs in the head and neck. Various forms of chemotherapy with drugs used alone or in combination have been tried. Regimens that include the drug cisplatinum in combination with other agents have been said to be superior. Cisplatinum alone is known to be the best single agent for end stage (very advanced) squamous cell carcinoma of the head and neck. VAC, a combination of vincristine, adriamycin and cyclophosphamide, is also known to be effective. In this study, 16 patients who had end stage squamous cell carcinoma of the head and neck were treated with cisplatinum alternating with VAC. Eight of the study patients had treatment beginning with cisplatinum followed by VAC; the other eight began with VAC, followed by cisplatinum. The authors originally planned to have 20 patients in the study, but did not because they found that the first 16 patients did less well than those who had received cisplatinum alone in a previous study, in which patients survived for an average of 180 days. In another previous study, patients survived with no treatment for an average of 70 days. The median survival time in this study of VAC and cisplatinum was 62 days, and only two patients achieved any response at all. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990